Systemic ±8-OH-DPAT dose- and receptor-dependently reduces ALO AIMs expression. In counterbalanced within-subjects designs, one group of L-DOPA-primed rats (n = 8) received pre-treatment with vehicle (VEH) or the 5-HT1AR agonist ±8-OH-DPAT (D-0.1 or 1.0 mg/kg, i.p.) 5 min after treatments of L-DOPA + benserazide (12 + 15 mg/kg, i.p.), after which (A) axial, limb, and orolingual AIMs (ALO AIMs) and (B) rotations were observed every 20 min for 2 hr. In a separate group of L-DOPA-primed rats (n = 7) 5 min after pretreatment with vehicle (VEH), 1.0 mg/kg of ± 8-OH-DPAT (D-1.0), 0.5 mg/kg of the 5-HT1AR antagonist WAY100635 (W-0.5 mg/kg, i.p.) or combined 8-OH-DPAT + WAY100635 (1.0 mg/kg + 0.5 mg/kg, i.p.; D+W), rats received treatments of L-DOPA + benserazide (12 + 15 mg/kg, i.p.), after which (C) ALO AIMs and (D) rotations were assessed every 20 min for 2 hr. Symbols represent averaged ALO AIMs and net rotations ± SEM observed at each time point of testing. ALO AIMs were analyzed by nonparametric Friedman ANOVAs. Two-way parametric ANOVAs were used for analysis of rotations. Post hoc comparisons denote significant differences between treatments as indicated. *P < 0.05 vs. VEH, +P < 0.05 vs. D-0.1, #P < 0.05 vs. D+W.